Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer

References

• Cancer Incidence in Finland. Finnish Cancer Registry, Helsinki2000.
   Google Scholar
• Budendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578–83
   PubMedGoogle Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588–94
   PubMed Web of Science ®Google Scholar
• Oefelein MG, Ricchuiti V, Conrad W, Seffel A, Bodner D, Goldman R, et al. Skeletal fractures associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patient with prostate cancer. J Urol 2001; 166: 1724–8
   PubMed Web of Science ®Google Scholar
• Salminen EK, Portin R, Korpela J, Helenius H, Parvinen L-M, Backman H, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003; 89: 971–6
   PubMed Web of Science ®Google Scholar
• Rodan GA. The development and function of the skeleton and bonemetastases. Cancer 2003; 97: 726–32
   PubMed Web of Science ®Google Scholar
• Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Yam LT. Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta 2002; 326: 113–22
   PubMedGoogle Scholar
• Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783–91
   PubMed Web of Science ®Google Scholar
• Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001; 47: 597–600
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004; 34: 187–94
   PubMed Web of Science ®Google Scholar
• Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaatanen HK. Tartrate resistant acid phosphatase 5B: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337–45
   PubMed Web of Science ®Google Scholar
• Eastham JA. Bishosphanates and prostate cancer: Maintaining bone integrity and quality of life. Am J Urol Review 2004; 2(Suppl 2)5–8
   Google Scholar
• Tu SM, Millikan RE, Mengistu B, Delpassand SE, Amato RJ, Pagliaro LC. Bone targeted therapy for advanced androgen.independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001; 357: 336–41
   PubMed Web of Science ®Google Scholar
• Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000; 48: 1443–6
   PubMedGoogle Scholar
• Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439
   PubMed Web of Science ®Google Scholar
• Shahinian V, Kuo Y-F, Freeman J, Goodwin J. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154–64
   PubMed Web of Science ®Google Scholar
• Oeflein MG, Ricchiuti M, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. Am J Urol Rev 2004; 2(Suppl 2)16–20
   Google Scholar
• Tamada D, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastatses of patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001; 19: 45–51
   PubMedGoogle Scholar
• Morote J, M'hammed YI, Martinez E, Esquena S, Lorente JA, Gelabert A. Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. Urology 2002; 59: 277–80
   PubMedGoogle Scholar
• Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005; 103: 237–41
   PubMed Web of Science ®Google Scholar
• Green JR. Skeletal complications of Prostate Cancer: Pathophysiology and Therapeutic Potential of Bisphosphonates. Acta Oncol 2005; 44: 284–94
   Google Scholar